Toagosei Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
1.6M | -0.75% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.4M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
908.6K | +6.74% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
774.3K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
636.0K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
465.7K | 0.00% |
Dividend History 3Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥65 | +8.3% |
| 2024 | ¥60 | +13.2% |
| 2023 | ¥53 | +47.2% |
| 2022 | ¥36 | 0.0% |
| 2021 | ¥36 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥156,313M | ¥160,825M | ¥159,371M | ¥167,594M |
| Gross Profit | ¥45,339M | ¥42,933M | ¥41,367M | ¥45,712M |
| Operating Income | ¥17,677M | ¥14,383M | ¥12,501M | ¥14,235M |
| Pretax Income | ¥18,895M | ¥17,414M | ¥17,225M | ¥16,705M |
| Net Income | ¥13,771M | ¥12,494M | ¥12,179M | ¥11,877M |
| EPS | ¥108.14 | ¥101.31 | ¥102.78 | ¥104.56 |
| Operating Margin | 11.31% | 8.94% | 7.84% | 8.49% |
| Balance Sheet | ||||
| Total Assets | ¥258,955M | ¥265,135M | ¥272,285M | ¥278,020M |
| Total Equity | ¥201,762M | ¥205,969M | ¥211,509M | ¥212,585M |
| Total Liabilities | ¥57,193M | ¥59,166M | ¥60,776M | ¥65,435M |
| Cash | ¥52,457M | ¥40,366M | ¥39,108M | ¥30,821M |
| Interest-bearing Debt | ¥11,495M | ¥12,375M | ¥12,345M | ¥12,302M |
| Equity Ratio | 77.91% | 77.68% | 77.68% | 76.46% |
| D/E Ratio | 0.06 | 0.06 | 0.06 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥21,219M | ¥10,988M | ¥21,638M | ¥20,183M |
| Investing CF | -¥10,239M | -¥3,579M | -¥3,528M | -¥13,594M |
| Financing CF | -¥8,644M | -¥9,464M | -¥15,524M | -¥14,507M |
| Free CF | ¥9,703M | -¥9,307M | ¥9,978M | -¥1,860M |
| Efficiency | ||||
| ROE | 6.83% | 6.07% | 5.76% | 5.59% |
| ROA | 5.32% | 4.71% | 4.47% | 4.27% |
Latest IR Information
-
Notice Regarding the Status of Treasury Stock Acquisition (Acquisition of Treasury Stock Based on the Provisions of Article 165, Paragraph 2 of the Companies Act)
From February 13 to February 28, 2026, Towa Pharmaceutical Co., Ltd. acquired 1,150,000 shares of treasury stock at a total value of 2,105,075,000 yen.
Read more -
2026-2028 Medium-Term Management Plan
The 2026-2028 medium-term management plan targets net sales of 180 billion yen, operating income of 18 billion yen, and EPS of 130 yen/share, emphasizing proactive investments in growth areas and sustainable social contribution.
Read more -
Fiscal Year Ending December 2025 Earnings Presentation Materials
For the fiscal year ending December 2025, net sales amounted to 162.312 billion yen (Year-over-Year (YoY) -3.2%), operating income was 14.18 billion yen (YoY -0.4%), and net income attributable to owners of parent was 12.766 billion yen (YoY +7.5%), recording...
Read more -
Notice Regarding the Results of Treasury Stock Acquisition through Off-Auction Own Share Buyback Transaction (ToSTNeT-3)
Announced the acquisition of 1,150,000 shares of treasury stock on February 13, 2026, for a total of 2,105,075,000 yen (1,830.5 yen per share).
Read more -
Notice Regarding the Resolution on Matters Concerning Share Buyback (Share Buyback Based on the Provisions of Article 165, Paragraph 2 of the Companies Act)
Share buyback upper limit of 2,000,000 shares, total acquisition amount of 3,000 million yen, acquisition period from February 13, 2026 to December 31, 2026 have been decided.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,850
Rating Score: 1.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
3DC Inc. announced that it has received funding from Toagosei Co., Ltd. - marketscreener.com ↗
Company Information
About
Toagosei Co., Ltd. manufactures chemical products. The company operates through Core Chemicals Business, Polymer/Oligomer Business, Adhesive Materials Business, High-performance Materials Business, Resin Processed Products Business, and Other segments. It offers commodity chemicals, such as liquid caustic soda, liquid chlorine, synthetic hydrochloric acid, sodium hypochlorite, caustic potash, super potash, iron perchloride solution, and Aron Zia Clean 200 hypochlorous acid solution; acrylic acid, acrylic esters, acrylamide tertiary butyl sulfonic acid, and ethylene carbonate; and oxygen, nitrogen, and argon industrial gases. The company also provides dispersants, thickeners, scale inhibitors, pressure sensitive adhesives, binders, paint vehicles, gelling agents, graft polymers, ARUFON, and macromonomers acrylic polymer products, as well as polymer flocculant; and adhesive materials, including instant glue, Aron Alpha, light-curable adhesives, high functional reactive adhesives, hot melt adhesives, film adhesives, silsesquioxane derivative, and powder paints. In addition, it offers high-purity inorganic chemicals, inorganic functional materials, and cellulose nano fiber performance chemicals; construction and civil engineering products comprising acrylic rubber protective coatings and waterproofing materials. The company operates in Japan, the United States, China, Taiwan, Hong Kong, Singapore, Thailand, Vietnam, Korea, and internationally. Toagosei Co., Ltd. was founded in 1933 and is headquartered in Minato, Japan.
